Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Isolated airways in equine respiratory pharmacology: They never lie.

Calzetta L, Pistocchini E, Ritondo BL, Roncada P, Cito G, Britti D, Matera MG.

Pulm Pharmacol Ther. 2019 Sep 22;59:101849. doi: 10.1016/j.pupt.2019.101849. [Epub ahead of print]

PMID:
31553927
2.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Sep 11;59:101841. doi: 10.1016/j.pupt.2019.101841. [Epub ahead of print]

PMID:
31520718
3.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1.

PMID:
31474120
4.

Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?

Liccardi G, Calzetta L, Milanese M, Bilò MB, Rogliani P.

Int Arch Allergy Immunol. 2019;180(2):142-143. doi: 10.1159/000501796. Epub 2019 Aug 14. No abstract available.

PMID:
31412331
5.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

6.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002
7.

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D.

Respir Med. 2019 Jul - Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.

PMID:
31228775
8.

Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.

Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG.

Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27. Review.

PMID:
31147200
9.

Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

Matera MG, Calzetta L, Rogliani P, Cazzola M.

Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. Review.

PMID:
31136930
10.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.

Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L.

Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.

11.

Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference.

Calzetta L, Crupi R, Roncada P, Pistocchini E, di Cave D, Rossi I, Cito G, Jacobson GA, Britti D.

Equine Vet J. 2019 May 27. doi: 10.1111/evj.13137. [Epub ahead of print]

PMID:
31132169
12.

Monoclonal antibodies in severe asthma: is it worth it?

Calzetta L, Matera MG, Rogliani P.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):517-520. doi: 10.1080/17425255.2019.1621837. Epub 2019 May 23.

PMID:
31104515
13.

Response.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 May;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028. No abstract available.

PMID:
31060694
14.

Bronchodilators in subjects with asthma-related comorbidities.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Respir Med. 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001. Epub 2019 Apr 3. Review.

PMID:
31047116
15.

Cardiovascular Disease in Chronic Respiratory Disorders and Beyond.

Rogliani P, Cazzola M, Calzetta L.

J Am Coll Cardiol. 2019 May 7;73(17):2178-2180. doi: 10.1016/j.jacc.2018.11.068. No abstract available.

PMID:
31047005
16.

Frequency of allergic sensitization to Can f 5 in North East Italy. An analysis of 1403 ISACs 112 (Component Resolved Diagnosis) collected retrospectively.

Villalta D, Milanese M, Da Re M, Sabatino G, Sforza M, Calzetta L, Liccardi G.

Eur Ann Allergy Clin Immunol. 2019 Jul;51(4):186-189. doi: 10.23822/EurAnnACI.1764-1489.89. Epub 2019 Apr 15.

17.

Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.

Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG.

Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.

PMID:
30876907
18.

Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it.

Liccardi G, Calzetta L, Milanese M, Passalacqua G, Rogliani P.

J Allergy Clin Immunol. 2019 Apr;143(4):1657-1658. doi: 10.1016/j.jaci.2018.12.1007. Epub 2019 Feb 10. No abstract available.

PMID:
30745148
19.

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J.

Expert Opin Pharmacother. 2019 Apr;20(6):737-750. doi: 10.1080/14656566.2019.1570133. Epub 2019 Feb 1. Review.

PMID:
30707637
20.

Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.

Calzetta L, Cazzola M, Matera MG, Rogliani P.

Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.

PMID:
30660781
21.

Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.

Cazzola M, Page C, Calzetta L, Matera MG.

Pharm Pat Anal. 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030. Epub 2019 Jan 18.

PMID:
30657422
22.

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 4;13:3115-3130. doi: 10.2147/COPD.S170606. eCollection 2018.

23.

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.

Cazzola M, Rogliani P, Calzetta L, Matera MG.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801586. doi: 10.1183/13993003.01586-2018. Print 2018 Dec. Review.

PMID:
30309975
24.

Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life.

Liccardi G, Calzetta L, Milanese M, Scaglione M, Rogliani P.

Ann Allergy Asthma Immunol. 2018 Oct;121(4):512-513. doi: 10.1016/j.anai.2018.07.039. No abstract available.

PMID:
30290895
25.

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).

Calzetta L, Hanania NA, Dini FL, Goldstein MF, Fairweather WR, Howard WW, Cazzola M.

Pulm Pharmacol Ther. 2018 Dec;53:20-26. doi: 10.1016/j.pupt.2018.09.007. Epub 2018 Sep 13.

26.

Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport.

Liccardi G, Calzetta L, Milanese M, Maniscalco M, Salzillo A, Rogliani P.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1808-1809. doi: 10.1016/j.jaip.2018.05.034. No abstract available.

PMID:
30197076
27.

Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study.

Liccardi G, Calzetta L, Apicella G, Baldi G, Berra A, Califano F, Ciccarelli A, Cutajar M, D'Amato M, De Crescenzo G, Di Maro E, Gargano D, Giannattasio D, Inciso G, Lo Schiavo M, Madonna F, Maniscalco M, Montera C, Papa G, Pedicini A, Pio R, Salzillo A, Stanziola A, Rogliani P, Musarra A.

Eur Ann Allergy Clin Immunol. 2019 Jan;51(1). doi: 10.23822/EurAnnACI.1764-1489.65. Epub 2018 Aug 1.

28.

Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.

Calzetta L, Matera MG, Rogliani P, Cazzola M.

Expert Rev Respir Med. 2018 Aug;12(8):693-708. doi: 10.1080/17476348.2018.1495562. Epub 2018 Jul 17. Review.

PMID:
29972340
29.

Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?

Cazzola M, Matera MG, Rogliani P, Calzetta L.

Expert Opin Investig Drugs. 2018 Jul;27(7):573-581. doi: 10.1080/13543784.2018.1492548. Epub 2018 Jul 4. Review.

PMID:
29972333
30.

Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.

Matera MG, Calzetta L, Gritti G, Gallo L, Perfetto B, Donnarumma G, Cazzola M, Rogliani P, Donniacuo M, Rinaldi B.

Eur J Pharmacol. 2018 Aug 5;832:114-119. doi: 10.1016/j.ejphar.2018.05.023. Epub 2018 May 18.

PMID:
29782855
31.

Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?

Liccardi G, Calzetta L, Milanese M, Salzillo A, Apicella G, Matera MG, Rogliani P.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1093-1094. doi: 10.1016/j.jaip.2018.01.029. No abstract available.

PMID:
29747978
32.

Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?

Liccardi G, Calzetta L, Milanese M, Salzillo A, Manzi F, Ferrari M, Rogliani P.

COPD. 2018 Jun;15(3):310-311. doi: 10.1080/15412555.2018.1459533. Epub 2018 May 7.

PMID:
29733688
33.

Efficacy and safety profile of xanthines in COPD: a network meta-analysis.

Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M.

Eur Respir Rev. 2018 May 2;27(148). pii: 180010. doi: 10.1183/16000617.0010-2018. Print 2018 Jun 30. Review.

34.

The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.

Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L.

Expert Opin Drug Saf. 2018 Jun;17(6):589-596. doi: 10.1080/14740338.2018.1472232. Epub 2018 May 14. Review.

PMID:
29716427
35.

Impact of doxofylline in COPD: A pairwise meta-analysis.

Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG.

Pulm Pharmacol Ther. 2018 Aug;51:1-9. doi: 10.1016/j.pupt.2018.04.010. Epub 2018 Apr 26. Review.

36.

Geographical characteristics influencing the risk of poisoning in pet dogs: Results of a large population-based epidemiological study in Italy.

Calzetta L, Roncada P, Piras C, Soggiu A, Liccardi G, Mattei M, Pistocchini E.

Vet J. 2018 May;235:63-69. doi: 10.1016/j.tvjl.2018.04.003. Epub 2018 Apr 6.

PMID:
29704941
37.

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P.

Respir Res. 2018 Apr 12;19(1):65. doi: 10.1186/s12931-018-0770-7.

38.

N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.

Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG.

Biomed Pharmacother. 2018 Jul;103:1-8. doi: 10.1016/j.biopha.2018.04.011. Epub 2018 Apr 24.

39.

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy.

Calzetta L, Matera MG, Cazzola M.

Curr Opin Pharmacol. 2018 Jun;40:95-103. doi: 10.1016/j.coph.2018.03.011. Epub 2018 Apr 4. Review.

PMID:
29626716
40.

Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.

Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2018 Jun;50:28-37. doi: 10.1016/j.pupt.2018.03.004. Epub 2018 Mar 30.

PMID:
29609004
41.

Is ICS-LAMA an alternative option to treat patients with COPD?

Rogliani P, Calzetta L, Cazzola M.

Lancet Respir Med. 2018 May;6(5):316-317. doi: 10.1016/S2213-2600(18)30139-5. Epub 2018 Apr 5. No abstract available.

PMID:
29605621
42.

Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways.

Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG.

J Vet Pharmacol Ther. 2018 Aug;41(4):546-554. doi: 10.1111/jvp.12504. Epub 2018 Mar 26.

PMID:
29582435
43.

How does race/ethnicity influence pharmacological response to asthma therapies?

Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):435-446. doi: 10.1080/17425255.2018.1449833. Epub 2018 Mar 12. Review.

PMID:
29528249
44.

Benralizumab for the treatment of asthma.

Matera MG, Rogliani P, Calzetta L, Canonica GW, Cazzola M.

Drugs Today (Barc). 2017 Dec;53(12):633-645. doi: 10.1358/dot.2017.53.12.2736670. Review.

PMID:
29517082
45.

A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD.

Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M.

Expert Opin Drug Saf. 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786. Epub 2018 Mar 8.

PMID:
29505318
46.

Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD.

Shute JK, Puxeddu E, Calzetta L.

Curr Opin Pharmacol. 2018 Jun;40:39-45. doi: 10.1016/j.coph.2018.01.006. Epub 2018 Feb 20. Review.

PMID:
29455115
47.

Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how.

Calzetta L, Matera MG, Rogliani P, Cazzola M.

Expert Rev Respir Med. 2018 Apr;12(4):261-264. doi: 10.1080/17476348.2018.1442216. Epub 2018 Feb 19. No abstract available.

PMID:
29451042
48.

Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study.

Liccardi G, Calzetta L, Baldi G, Berra A, Billeri L, Caminati M, Capano P, Carpentieri E, Ciccarelli A, Crivellaro MA, Cutajar M, D'Amato M, Folletti I, Gani F, Gargano D, Giannattasio D, Giovannini M, Lombardi C, Schiavo ML, Madonna F, Maniscalco M, Meriggi A, Micucci C, Milanese M, Montera C, Paolocci G, Parente R, Pedicini A, Pio R, Puggioni F, Russo M, Salzillo A, Scavalli P, Scichilone N, Sposato B, Stanziola A, Steinhilber G, Vatrella A, Rogliani P, Passalacqua G; Italian Allergic Respiratory Diseases Task Force.

Clin Mol Allergy. 2018 Feb 2;16:3. doi: 10.1186/s12948-018-0081-z. eCollection 2018.

49.

Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue.

Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG.

Pulm Pharmacol Ther. 2018 Apr;49:88-94. doi: 10.1016/j.pupt.2018.01.010. Epub 2018 Jan 31.

PMID:
29408044
50.

Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis.

Calzetta L, Rogliani P, Page C, Roncada P, Pistocchini E, Soggiu A, Piras C, Urbani A, Matera MG.

Equine Vet J. 2018 Sep;50(5):594-601. doi: 10.1111/evj.12815. Epub 2018 Feb 23.

PMID:
29393535

Supplemental Content

Loading ...
Support Center